Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
| العنوان: | Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma |
|---|---|
| المؤلفون: | Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke B. Holmstroem, Lidwina D.V. Wever, Marloes van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, Alejandro Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A.M. Stevense-den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan-Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers-Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebaek, Lisbet R. Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, Aafke Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen |
| المساهمون: | Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical Biochemistry, CCA - Cancer Treatment and Quality of Life, AII - Cancer immunology, Landsteiner Laboratory, General Internal Medicine, Health Technology & Services Research, Health Technology Assessment (HTA), Medical Oncology, Erasmus MC other, Surgery, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy |
| المصدر: | New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOC The New England Journal of Medicine, 387, 2113-2125 New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233Test The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY The New England Journal of Medicine, 387, 23, pp. 2113-2125 |
| بيانات النشر: | MASSACHUSETTS MEDICAL SOC, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Adoptive, Cell- and Tissue-Based Therapy, Outcomes, Dermatology, Metastatic melanoma, Guidelines, Immunotherapy, Adoptive, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Lymphocytes, Tumor-Infiltrating, SDG 3 - Good Health and Well-being, Adoption, Humans, Melanoma/drug therapy, Lymphocytes, Tumor-Infiltrating, Melanoma, Skin Cancer, Treatments in Oncology, Cancer, General Medicine, Complete responses, Hematology/Oncology, Ipilimumab, n/a OA procedure, Adoptive cell therapy, Nivolumab, Ipilimumab/adverse effects, Immunotherapy |
| الوصف: | Item does not contain fulltext BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) have shown promising responses, but data from phase 3 trials are lacking to determine the role of TILs in treating advanced melanoma. METHODS: In this phase 3, multicenter, open-label trial, we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy (ipilimumab at 3 mg per kilogram of body weight). Infusion of at least 5×10(9) TILs was preceded by nonmyeloablative, lymphodepleting chemotherapy (cyclophosphamide plus fludarabine) and followed by high-dose interleukin-2. The primary end point was progression-free survival. RESULTS: A total of 168 patients (86% with disease refractory to anti-programmed death 1 treatment) were assigned to receive TILs (84 patients) or ipilimumab (84 patients). In the intention-to-treat population, median progression-free survival was 7.2 months (95% confidence interval [CI], 4.2 to 13.1) in the TIL group and 3.1 months (95% CI, 3.0 to 4.3) in the ipilimumab group (hazard ratio for progression or death, 0.50; 95% CI, 0.35 to 0.72; P |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1533-4406 0028-4793 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edf28a71e5a16116e2b0f59cdac9485aTest https://research.rug.nl/en/publications/9033fdbd-9e6f-4cca-a35b-50890da9f292Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....edf28a71e5a16116e2b0f59cdac9485a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15334406 00284793 |
|---|